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Identity 
Other names: RIPE3b1; KLRG1; Maf-A,: hMafA; L-
Maf 
HGNC (Hugo): MAFA 
Location: 8q24.3 




The MAFA open reading frame is encoded by a unique 
exon. The entire genomic organization and the putative 
existence of non-coding exons remain unknown. 
Transcription 
MAFA displays a restricted expression pattern. It is 





Maf oncoproteins are b-ZIP transcription factors that 
belong to the AP-1 super-family, which notably 
includes JUN and FOS. The Maf family contains seven 
members, which can be subdivided into two groups; the 
large and small Maf proteins. While the small Maf 
proteins, MAFF, MAFG and MAFK, are essentially 
composed of a b-Zip domain, the large Maf proteins, 
MAFA/L-MAF, MAFB, MAF/c-MAF and NRL 
contain an additional amino-terminal transactivation 
domain. MAFA was initially cloned in quail and 
chicken species and named MAFA and L-MAF, 
respectively. More recently, mammalian MAFA was 
cloned and identi-fied as an essential component of the 
RIPE3b1 complex, which binds the insulin promoter. 
 
Schematic representation of the MAFA protein structure. Critical residues involved in post-translational modifications are indicated by the 
color code. The kinases responsible for S14 and S65 phosphorylation in MAFA remain to be identified. GSK-3 phosphorylates the 
transactivation domain of MAFA, thereby inducing its ubiquitination and proteasome-dependent degradation. This is linked to an increase 
in MAFA transactivation. These phosphorylations are required for MAFA transforming activity. In contrast, sumoylation of MAFA 
transactivation domain decreases its transactivation activity. 
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Description 
MAFA, like all large Maf proteins, contains an amino-
terminal transactivation domain and a carboxy-terminal 
b-ZIP DNA binding domain. Large Maf proteins 
stimulate transcription of their target genes through 
their binding to two types of palindromic sequences 
called TRE- or CRE- type MARE (Maf Responsive 
Element) (TGCTGAC(G) TCAGCA). The leucine 
zipper domain allows the formation of homo- or hetero- 
dimers, an absolute pre-requisite for DNA binding. As 
homodimers, these proteins recognize palindromic 
sequences, with the basic domain contacting DNA 
directly. Among the AP-1 family, the Maf proteins are 
defined by the presence of an additional homolo-gous 
domain, called the Extended Homology Region (EHR) 
or ancillary domain, which also contacts DNA. 
Consequently, they recognize a longer palindromic 
sequence than other AP-1 family members. The MARE 
sequence is composed of a TRE or CRE core contacted 
by the basic domain and a TGC flanking sequence, 
which is recognized by the EHR domain. While the 
TGC motif is crucial for Maf binding, the TRE/CRE 
core can be more degenerate. MAFA transactivation 
activity and stability is regulated by post-trans-lational 
modifications (phosphorylation, ubiquityla-tion and 
sumoylation) mostly occuring on the transactivation 
domain. GSK-3 was identified as the major protein 
kinase regulating MAFA activity and oncogenic 
properties. 
Expression 
Endogenous MAFA protein is detected and phos-




During development, Maf proteins are involved early in 
specification and later in terminal differen-tiation. 
MAFA is involved in the regulation of insulin gene 
expression in pancreatic beta cells. Accordingly, 
MAFA ablation in mice leads to diabetes. 
Besides their roles during development, large Maf 
proteins, MAFA, MAFB, and MAF/c-MAF are also 
involved in oncogenesis. 
Homology 
MAFB and MAF/c-MAF are the closest MAFA 
homologs. The MAFA entire protein sequence shares 
52%, 48% and 40% identity with those of MAFB, 
MAF/c-MAF and NRL, respectively. MAFA DNA 
binding domain (EHR + b-ZIP) shares 82%, 83%, 64% 
and 55-60% identity with those of MAFB, MAF/c-
MAF, NRL and small MAFs, respectively. MAFA and 
JUN share 30% sequence identity in their b-ZIP 






Two cases reported translocations of MAFA to the 
immunoglobulin heavy-chain (IgH) locus, juxta-posing 
the MAFA gene with the strong enhancers of the IgH 
locus (meeting report, accurate description lacking). 
Oncogenesis 
Large Maf proteins, MAFA, MAFB, and MAF/c-MAF 
are bona fide oncogenes as demonstrated in tissue 
culture, animal models and in human cancers. MAFA 
displays the strongest transforming activity, in vitro. In 
human, MAF/c-MAF, MAFB and MAFA genes are 
translocated to the immunoglo-bulin heavy chain (IgH) 
locus in 8-10% of multiple myelomas. MAFA 
translocations are present in less than 1% of multiple 
myelomas. MAF/C-MAF over-expression plays a 
causative role in multiple myeloma by promoting 
proliferation and patholo-gical interactions with bone 
marrow stroma. 
The transforming activity of Maf proteins is context 
dependent and they can occasionally display tumor 
suppressor-like activity in specific cellular settings. 
Their transforming activity relies on overexpression 
and does not require an activating mutation (no 
activating mutation has been identified to be associated 
with human cancers). It is regulated by post-
translational modifications, notably phospho-rylation. 
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